[Infectious glomerulonephritis]

Hélène François-Pradier1

  • 1Service de médecine interne, immunologie clinique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

La Revue Du Praticien
|December 5, 2018
PubMed

Insights

Post-infectious glomerulonephritis (PIGN) is a kidney disease often seen in children after bacterial infections. While typically favorable, it’s now rarer and affects immunocompromised individuals, leading to more frequent kidney damage.

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Post-infectious glomerulonephritis (PIGN) is a common glomerular disease linked to bacterial infections.
  • Traditionally affecting young children with upper respiratory tract infections, PIGN presents with nephritic syndrome and characteristic renal histology.
  • Recent trends show PIGN is now rare in industrialized nations, primarily affecting immunocompromised populations, with increased risk of renal sequelae.

Purpose of the Study:

  • To review the epidemiology, pathophysiology, clinical presentation, and management of post-infectious glomerulonephritis.
  • To highlight the shift in PIGN demographics towards immunocompromised hosts and its impact on renal prognosis.
  • To discuss the underlying mechanisms involving complement pathways in PIGN.

Main Methods:

  • Review of existing literature on post-infectious glomerulonephritis.
  • Analysis of epidemiological data and clinical case studies.
  • Examination of histopathological findings and pathomechanisms, including complement system involvement.

Main Results:

  • PIGN typically manifests 15 days post-infection with nephritic syndrome.
  • Histology reveals exsudative endocapillary proliferation and subepithelial "hump-shaped" C3 deposits.
  • The disease is now infrequent, predominantly seen in immunocompromised patients, leading to poorer outcomes.

Conclusions:

  • Post-infectious glomerulonephritis pathogenesis involves immune complexes and complement activation.
  • The changing epidemiology of PIGN necessitates a re-evaluation of its clinical significance and management, especially in vulnerable populations.
  • Current treatment for PIGN remains symptomatic.